Study guide
22.1 Specimens, Diagnostic Results and Rater Quality
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
22.1 Specimens, Diagnostic Results and Rater Quality
Key Takeaways Explain This Topic AI
Specimen traceability extends from collection through processing, shipment and receipt.
Processing and transport parameters depend on actual study instructions.
Relevant external results require timely qualified review and appropriate action.
Last updated: October 2026
Specimens, Diagnostic Results and Rater Quality
A specimen can be collected correctly yet become unusable through misidentification, processing, storage or shipment. A valid diagnostic result can still fail to protect a participant if it never reaches a qualified reviewer. The ECO covers sample/diagnostic collection, shipment, verification, reporting and storage, including laboratories, imaging and raters. Monitoring should follow the complete process and its clinical consequences.
Use the actual protocol and laboratory/diagnostic instructions. Collection timing, containers, processing, temperature and shipping conditions depend on the analyte and method. There is no universal centrifuge speed, freezing temperature or shipping interval for all clinical samples. A monitor verifies the specified process rather than improvising technical parameters from memory.
Traceable collection and processing
Confirm participant code, required visit/time point, actual collection time and relevant preconditions. Record deviations honestly. A planned time and actual time answer different questions, especially for timed pharmacokinetic or safety assessments. A requisition preprinted with the planned time does not prove when collection occurred.
Relevant processing records should establish what happened, by whom and when, using suitable equipment and supplies. Labelled aliquots and storage locations should remain traceable to the original sample without inappropriate identifying information. If a label is unclear, follow a controlled investigation and correction process. Do not guess the participant or overwrite identifiers to match a convenient manifest.
Storage and shipment
- Step Main risk Monitoring evidence
- Collection Wrong participant, time or container Source, label and collection record
- Processing Untrained work or incorrect conditions Task records, timing and equipment evidence
- Storage Wrong location, excursion or mix-up Inventory, conditions and issue response
- Shipment Misrouting, delay or lost chain of custody Manifest, handoff, tracking and receipt
- Receipt/testing Rejection, missing sample or incomplete test Laboratory acknowledgement and result status
- Clinical review Important result not acted on Investigator review and documented follow-up
Shipping must follow applicable biosafety and transport requirements, using appropriately trained personnel. The CCRA lesson is to verify the authorised instructions, traceability and response to a problem; it is not to memorise one dangerous-goods category for every specimen. The study team should arrange the correct technical process for the actual material and destination.
A courier delay may affect sample suitability. Preserve the known collection, processing and shipping conditions and ask the responsible laboratory/sponsor function to evaluate the impact. A tracking status saying delivered does not establish the sample was accepted or analysed. Check rejections, missing tests and any need for a permitted repeat with the investigator.
Critical laboratory results
The investigator should have timely access to relevant external results affecting eligibility, treatment or safety and should review them appropriately. A portal timestamp can show a report became available; it may not establish that the treating team reviewed the critical finding. Confirm the alert and escalation process, including nights, weekends and absent primary contacts.
If a significant result lacks documented review, promptly involve qualified site staff and the sponsor as appropriate. The CRA should not diagnose the participant, prescribe treatment or wait for the next routine monitoring cycle. Determine whether medical assessment, an AE record, a dose decision or safety reporting is required under the protocol. Not every out-of-range result is automatically an AE; the investigator's assessment and collection instructions matter.
Imaging and raters
Diagnostic and endpoint quality can depend on acquisition methods, software, equipment, scoring conventions and rater training. Verify required certification and approved manuals, including changes. An otherwise clear image can be unsuitable if it omits a required view or uses the wrong acquisition method. A subjective rating can be biased if the assessor sees treatment information intended to remain concealed.
Preserve original outputs and relevant metadata. Where central review is used, clarify whether the local result, central result or both guide care and analysis. The investigator must receive clinically necessary information through an appropriate route; maintaining a scientific blind does not justify withholding urgent participant-safety information. Address the access boundary in the protocol and plans.
A reconciliation example
An EDC visit lists a completed safety panel, the shipment log shows two samples sent and the central laboratory reports one rejected specimen. Review whether the EDC records actual results, a planned collection or a completion assumption. Trace sample identifiers, rejection reason, investigator review and any permitted repeat. Correct the supported record with an audit trail; do not enter normal values because the participant looked well.
At closure reconcile unresolved samples, results and retained material under the protocol, consent and applicable requirements. Clarify storage or destruction authorisation and retain necessary records. The sample's physical disposition and the retention of associated clinical data are related but different decisions; completing one does not automatically complete the other.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .